Literature DB >> 22840696

Synthesis, DNA binding and antileishmanial activity of low molecular weight bis-arylimidamides.

Moloy Banerjee1, Abdelbasset A Farahat, Arvind Kumar, Tanja Wenzler, Reto Brun, Manoj M Munde, W David Wilson, Xiaohua Zhu, Karl A Werbovetz, David W Boykin.   

Abstract

The effects of reducing the molecular weight of the antileishmanial compound DB766 on DNA binding affinity, antileishmanial activity and cytotoxicity are reported. The bis-arylimidamides were prepared by the coupling of aryl S-(2-naphthylmethyl)thioimidates with the corresponding amines. Specifically, we have prepared new series of bis-arylimidamides which include 3a, 3b, 6, 9a, 9b, 9c, 13, and 18. Three compounds 9a, 9c, and 18 bind to DNA with similar or moderately lower affinity to that of DB766, the rest of these compounds either show quite weak binding or no binding at all to DNA. Compounds 9a, 9c, and 13 were the most active against Leishmania amazonensis showing IC(50) values of less than 1 μM, so they were screened against intracellular Leishmania donovani, showing outstanding activity with IC(50) values of 25-79 nM. Despite exhibiting little in vitro cytotoxicity these three compounds were quite toxic to mice.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22840696      PMCID: PMC3560421          DOI: 10.1016/j.ejmech.2012.06.058

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  22 in total

1.  Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.

Authors:  Denise da Gama Jaén Batista; Marcos Meuser Batista; Gabriel Melo de Oliveira; Patrícia Borges do Amaral; Joseli Lannes-Vieira; Constança Carvalho Britto; Angela Junqueira; Marli Maria Lima; Alvaro José Romanha; Policarpo Ademar Sales Junior; Chad E Stephens; David W Boykin; Maria de Nazaré Correia Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

2.  Diguanidino and "reversed" diamidino 2,5-diarylfurans as antimicrobial agents.

Authors:  C E Stephens; F Tanious; S Kim; W D Wilson; W A Schell; J R Perfect; S G Franzblau; D W Boykin
Journal:  J Med Chem       Date:  2001-05-24       Impact factor: 7.446

Review 3.  Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?

Authors:  François Chappuis; Shyam Sundar; Asrat Hailu; Hashim Ghalib; Suman Rijal; Rosanna W Peeling; Jorge Alvar; Marleen Boelaert
Journal:  Nat Rev Microbiol       Date:  2007-11       Impact factor: 60.633

4.  In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity.

Authors:  Dhiraj Kumar; Arpita Kulshrestha; Ruchi Singh; Poonam Salotra
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

5.  Novel arylimidamides for treatment of visceral leishmaniasis.

Authors:  Michael Zhuo Wang; Xiaohua Zhu; Anuradha Srivastava; Qiang Liu; J Mark Sweat; Trupti Pandharkar; Chad E Stephens; Ed Riccio; Toufan Parman; Manoj Munde; Swati Mandal; Rentala Madhubala; Richard R Tidwell; W David Wilson; David W Boykin; James Edwin Hall; Dennis E Kyle; Karl A Werbovetz
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

Review 6.  Sitamaquine (GlaxoSmithKline/Walter Reed Army Institute).

Authors:  Clive Yeates
Journal:  Curr Opin Investig Drugs       Date:  2002-10

7.  Synthesis of directly connected BODIPY oligomers through Suzuki-Miyaura coupling.

Authors:  Yosuke Hayashi; Shigeru Yamaguchi; Won Young Cha; Dongho Kim; Hiroshi Shinokubo
Journal:  Org Lett       Date:  2011-05-17       Impact factor: 6.005

Review 8.  Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004.

Authors:  Piero L Olliaro; Philippe J Guerin; Sibylle Gerstl; Astrid Aga Haaskjold; John-Arne Rottingen; Shyam Sundar
Journal:  Lancet Infect Dis       Date:  2005-12       Impact factor: 25.071

9.  Redox-active dinitrodiphenylthioethers against Leishmania: synthesis, structure-activity relationships and mechanism of action studies.

Authors:  Dawn A Delfín; Rachel E Morgan; Xiaohua Zhu; Karl A Werbovetz
Journal:  Bioorg Med Chem       Date:  2008-11-19       Impact factor: 3.641

10.  Synthesis and antiprotozoal activity of cationic 1,4-diphenyl-1H-1,2,3-triazoles.

Authors:  Stanislav A Bakunov; Svetlana M Bakunova; Tanja Wenzler; Maedot Ghebru; Karl A Werbovetz; Reto Brun; Richard R Tidwell
Journal:  J Med Chem       Date:  2010-01-14       Impact factor: 7.446

View more
  6 in total

1.  Antileishmanial Efficacy and Pharmacokinetics of DB766-Azole Combinations.

Authors:  April C Joice; Sihyung Yang; Abdelbasset A Farahat; Heidi Meeds; Mei Feng; Junan Li; David W Boykin; Michael Zhuo Wang; Karl A Werbovetz
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

2.  Studies on the antileishmanial mechanism of action of the arylimidamide DB766: azole interactions and role of CYP5122A1.

Authors:  Trupti Pandharkar; Xiaohua Zhu; Radhika Mathur; Jinmai Jiang; Thomas D Schmittgen; Chandrima Shaha; Karl A Werbovetz
Journal:  Antimicrob Agents Chemother       Date:  2014-06-02       Impact factor: 5.191

3.  In vitro and in vivo studies of the biological activity of novel arylimidamides against Trypanosoma cruzi.

Authors:  J S De Araújo; C F Da Silva; D G J Batista; P B Da Silva; M B Meuser; C A F Aiub; M F V da Silva; C F Araújo-Lima; M Banerjee; A A Farahat; C E Stephens; A Kumar; D W Boykin; M N C Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2014-03-03       Impact factor: 5.191

Review 4.  Novel amidines and analogues as promising agents against intracellular parasites: a systematic review.

Authors:  M N C Soeiro; K Werbovetz; D W Boykin; W D Wilson; M Z Wang; A Hemphill
Journal:  Parasitology       Date:  2013-04-08       Impact factor: 3.234

5.  Synthesis and pharmacological evaluation of mono-arylimidamides as antileishmanial agents.

Authors:  Xiaohua Zhu; Abdelbasset A Farahat; Meena Mattamana; April Joice; Trupti Pandharkar; Elizabeth Holt; Moloy Banerjee; Jamie L Gragg; Laixing Hu; Arvind Kumar; Sihyung Yang; Michael Zhuo Wang; David W Boykin; Karl A Werbovetz
Journal:  Bioorg Med Chem Lett       Date:  2016-03-25       Impact factor: 2.823

6.  Synthesis, anti-bacterial and anti-protozoal activities of amidinobenzimidazole derivatives and their interactions with DNA and RNA.

Authors:  Andrea Bistrović; Luka Krstulović; Ivana Stolić; Domagoj Drenjančević; Jasminka Talapko; Martin C Taylor; John M Kelly; Miroslav Bajić; Silvana Raić-Malić
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.